A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Antibodies from the mother passed through placenta safeguard newborns from birth
- Protection achievable with 2-week gap before premature birth
- Vaccination during third trimester still offers significant infant protection
Compelling evidence from current research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study carried out throughout England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s findings have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research offers healthcare professionals and prospective parents with trust in the vaccine’s established performance across varied populations and settings.
The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction emphasises the vaccine’s vital importance in protecting against serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research analysed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology assessed actual clinical results rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when delivered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and the hazards
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it perilously hard for affected infants to feed and breathe effectively. Parents commonly see their babies struggling visibly, their chests heaving as they try to pull enough air into their weakened respiratory system. Whilst most infants recover with supportive care, a limited though important group succumb from RSV-related complications yearly, making immunisation programmes a vital health service imperative for defending the most vulnerable and youngest people in our communities.
- RSV triggers inflammation in lungs, causing serious respiratory problems in infants
- Approximately half of infants catch the infection during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK infants require serious hospital care for RSV annually
- A small number of babies succumb to RSV related complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have stressed the value of pregnant women getting their jab at the optimal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies through the placenta.
The messaging from health authorities stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional variations in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These regional differences reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data shows robust and reliable protection irrespective of geographical location.
- NHS trusts launching varied communication campaigns to engage with pregnant women
- Inconsistencies across regions in vaccine uptake rates across England require targeted improvement
- Local healthcare systems modifying schemes to suit local requirements and situations
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness translates into concrete gains for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this safeguarding intervention, the 80% reduction in admissions equates to thousands of infants shielded from critical disease. Parents no longer face the troubling prospect of seeing their babies gasping for air or struggle to eat, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the terrain of neonatal breathing health, offering expectant mothers a active means to shield their most at-risk babies during those vital initial period.
For families like that of Malachi, whose serious RSV infection resulted in profound brain damage, the vaccine’s availability carries deep personal significance. His mother’s support of the jab emphasises the profound consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to expectant mothers navigating their final trimester, converting what was once an predictable seasonal threat into a controllable health concern.